DSIP (Delta Sleep-Inducing Peptide)

DSIP is a small peptide first discovered in brain blood, named for its apparent link to deep, slow-wave sleep.

It's studied in cognitive and longevity research — how the brain enters deep sleep and how stress hormones normalize during rest.

Early lab EEG studies suggested it promotes deep sleep. Human evidence is limited and not established.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

DSIP is an unapproved investigational peptide. It is not FDA-approved for insomnia or any use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

High doses alter stress-hormone baselines in animal models.

• Schoenenberger GA. DSIP--a neuromodulator. Eur Neurol. 1984.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.